Soleno Therapeutics (SLNO) saw its stock price surge 5.70% in pre-market trading on Tuesday, following a significant corporate announcement. The biopharmaceutical company revealed its entry into a $100 million Accelerated Share Repurchase Agreement, a move that has evidently excited investors.

Share repurchase programs, also known as buybacks, are often viewed positively by the market as they signal management's confidence in the company's financial health and future prospects. By reducing the number of outstanding shares, buybacks can potentially increase earnings per share and boost shareholder value. The substantial size of this agreement, at $100 million, suggests a strong commitment from Soleno Therapeutics to enhance shareholder returns.

While the full details and implications of this share repurchase agreement are yet to be fully analyzed, the immediate market reaction indicates that investors are optimistic about this strategic move. As trading opens, market participants will be closely watching to see if this pre-market momentum continues and how it might impact Soleno Therapeutics' long-term valuation.